Sign in →

Test Code SHBG1 Sex Hormone-Binding Globulin, Serum


Specimen Required


Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Useful For

Diagnosis and follow-up of women with signs or symptoms of androgen excess (eg, polycystic ovarian syndrome and idiopathic hirsutism)

 

An adjunct in monitoring sex-steroid and antiandrogen therapy

 

An adjunct in the diagnosis of disorders of puberty

 

An adjunct in the diagnosis and follow-up of anorexia nervosa

 

An adjunct in the diagnosis of thyrotoxicosis (tissue marker of thyroid hormone excess)

 

A possible adjunct in diagnosis and follow-up of insulin resistance and cardiovascular and type 2 diabetes risk assessment, particularly in women

Method Name

Immunoenzymatic Assay

Reporting Name

Sex Hormone-Binding Globulin, S

Specimen Type

Serum

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  90 days
  Ambient  7 days

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross icterus OK

Clinical Information

Sex hormone-binding globulin (SHBG), a 95 kDa homodimer, is the blood transport protein for testosterone and estradiol. SHBG is mainly produced in the liver and has a half-life of approximately seven days. SHBG binds reversibly to sex steroids. SHBG has a relatively high-binding affinity to dihydrotestosterone (DHT), medium affinity to testosterone and estradiol, and exhibits a low affinity to estrone, dehydroepiandrosterone, androstenedione, and estriol. Albumin, which exists at physiologically higher concentrations than SHBG, also binds to sex steroids, although with a much lower binding affinity (eg, about 100 times lower for testosterone).

 

Decreased SHBG serum concentrations are associated with conditions in which elevated androgen concentrations are present, or the effect of androgen on its target organs is excessive. Because of the high-binding affinity of SHBG to DHT, as compared to estradiol, SHBG has profound effects on the balance between bioavailable androgens and estrogens. Increased SHBG concentrations may be associated with signs and symptoms of hypogonadism in men, while decreased concentrations can result in androgenization in women. SHBG is regulated by insulin, and a low SHBG concentration often indicates insulin resistance and, consequently, may be a predictor of type 2 diabetes.

 

Endogenous or exogenous thyroid hormones or estrogens increase SHBG concentrations. In men, there is also an age-related gradual rise, possibly secondary to the mild age-related fall in testosterone production. This process can result in bioavailable testosterone concentrations that are much lower than would be expected based on total testosterone measurements alone.

Reference Values

CHILDREN:

Males

 

Tanner Stages

Mean Age

Reference Interval (nmol/L)

Stage I

10.4

17-135

Stage II

11.1

21-114

Stage III

12.7

12-138

Stage IV

14.5

7.7-67

Stage V

14.2

3.9-40

Females

Tanner Stages

Mean Age

Reference Interval (nmol/L)

Stage I

10.5

16-182

Stage II

10.9

24-121

Stage III

12.5

18-87

Stage IV

14

7.7-108

Stage V

14.9

10-79

 

ADULTS:

Males

≥18 years: 13.3-89.5 nmol/L

Females

18-46 years: 18.2-135.5 nmol/L

47-91 years: post-menopausal: 16.8-125.2 nmol/L

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

84270

Day(s) Performed

Monday through Saturday

Report Available

1 to 3 days